Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

Historical Holders from Q3 2020 to Q3 2025

Symbol
PRLD on Nasdaq
CUSIP
74065P101
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
44.2M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
27.2M
Holdings value
$39.1M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
44
Number of buys
12
Number of sells
-29
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 23.5% $8.01M 10.3M Baker Bros. Advisors LP Jun 12, 2025
Vaddi Krishna 13.8% +43% $3.9M $554K 6.4M +16.6% Vaddi Krishna Mar 31, 2025
INCYTE CORP 9.9% $6.3M 4.37M INCYTE CORP Nov 3, 2025

Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 27.2M $39.1M +$249K $1.44 44
2025 Q2 27.2M $22M -$2.4M $0.81 49
2025 Q1 30.3M $23.3M -$2.26M $0.77 56
2024 Q4 32.1M $41M -$13M $1.28 59
2024 Q3 35.8M $74M +$3.11M $2.07 69
2024 Q2 33.9M $129M -$1.3M $3.81 59
2024 Q1 34.2M $162M -$2.33M $4.74 55
2023 Q4 34.7M $148M -$6.55M $4.27 55
2023 Q3 36.6M $113M +$1.04M $3.09 57
2023 Q2 36.3M $163M +$31.3M $4.50 52
2023 Q1 31.5M $180M +$1.73M $5.70 53
2022 Q4 31.2M $188M -$4.39M $6.04 58
2022 Q3 31.8M $210M -$5.2M $6.61 48
2022 Q2 32.2M $168M -$6.71M $5.22 51
2022 Q1 32.5M $224M -$9.98M $6.90 60
2021 Q4 35.1M $437M -$27.3M $12.45 71
2021 Q3 35.9M $1.12B +$46.3M $31.25 59
2021 Q2 34.5M $987M +$53.3M $28.63 57
2021 Q1 32.5M $1.41B -$97.8M $43.33 59
2020 Q4 34.7M $2.47B +$136M $71.55 50
2020 Q3 33.3M $1B +$1B $30.13 38